论文部分内容阅读
应用大剂量国产尿激酶溶栓治疗急性心肌梗塞患者 ,发病距溶栓 6h内 12例 ,6～ 12h 8例 ,超过 12h 6例。应用大剂量国产尿激酶溶栓治疗发病 6h内的急性脑梗塞患者 10例。结果 :发病 6h内急性心肌梗塞患者冠状动脉再通率为 75% ,发病 6～ 12h再通率为 50 % ,超过 12h再通率为 33.3% ,急性脑梗塞发病距溶栓 6h内基本痊愈率达 70 %。结论 :应用大剂量国产尿激酶早期溶栓治疗急性心肌梗塞和急性脑梗塞有较好疗效 ,而且安全 ,急性心肌梗塞栓塞血管的再通率有时间依赖性 ,是溶栓临床疗效最重要的影响因素之一。
Application of high-dose domestic urokinase thrombolytic therapy in patients with acute myocardial infarction, onset within 6h from the thrombolytic therapy in 12 cases, 6 ~ 12h 8 cases, more than 12h in 6 cases. Application of high-dose domestic urokinase thrombolytic therapy within 6h of acute cerebral infarction in 10 patients. Results: The recanalization rate of coronary artery was 75% in acute intracerebral infarction within 6h, the recanalization rate was 50% in 6 ~ 12h and the recanalization rate was 33.3% in 12h. The basic cure rate of acute cerebral infarction within 6h after thrombolytic therapy Up to 70%. Conclusions: The early thrombolytic therapy with high-dose domestic urokinase has a good curative effect on acute myocardial infarction and acute cerebral infarction, and the time-dependent reperfusion rate of safe and acute myocardial infarction embolism is the most important effect of clinical efficacy of thrombolysis One of the factors.